Avelumab

Drug Profile

Avelumab

Alternative Names: Anti-PD-L1 monoclonal antibody - EMD Serono; Anti-PD-L1 monoclonal antibody - Merck; BAVENCIO; MSB-0010718C; PF-06834635

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator EMD Serono; Merck KGaA
  • Developer EMD Serono; Hospices Civils de Lyon; Merck KGaA; National Cancer Institute (USA); Pfizer; Syndax Pharmaceuticals; University of California, San Diego; Vanderbilt-Ingram Cancer Center; VAXIMM; Verastem
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD274 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Merkel cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Merkel cell carcinoma
  • Registered Urogenital cancer
  • Phase III Breast cancer; Diffuse large B cell lymphoma; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma
  • Phase II Endometrial cancer; Gestational trophoblastic disease; Glioblastoma; Intestinal cancer; Nasopharyngeal cancer; Recurrent respiratory papillomatosis; Thymoma
  • Phase I/II Fallopian tube cancer; Peritoneal cancer
  • Phase I Acute myeloid leukaemia; Hodgkin's disease; Solid tumours
  • Preclinical Colorectal cancer

Most Recent Events

  • 10 May 2017 EpiThany, Merck and Pfizer agree to co-develop EP 101, in combination with avelumab, for Breast cancer
  • 10 May 2017 EpiThany, Merck and Pfizer plan a phase II trial for Breast Cancer (Combination therapy, Neoadjuvant therapy)
  • 09 May 2017 VAXIMM, Merck and Pfizer agree to co-develop VXM 01, in combination with Avelumab, for Glioblastoma and Colorectal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top